Evidence map›Paper›PMID 35785793›Full record

ReviewThe Lancet. Infectious diseases2022

Demographic and clinical characteristics of confirmed human monkeypox virus cases in individuals attending a sexual health centre in London, UK: an observational analysis.

Nicolò Girometti, Ruth Byrne, Margherita Bracchi, Joseph Heskin, Alan McOwan, Victoria Tittle, Keerti Gedela, Christopher Scott, Sheel Patel, Jesal Gohil and 14 more

Registry-linked trialOpen access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in The Lancet. Infectious diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05597735 (A Phase III, Multi-country, Randomized, Placebo-controlled, Double-blinded Trial to Assess the Efficacy and Safety of Tecovirimat Antiviral Treatment for Patients With Monkeypox Virus Disease), which is not on this map. Cited by 254 papers, 12 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
254citing papers in PubMed, 12 pooled it
35.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05597735 phase3active not recruitingnot on this mapstarted 2023, after this paper: background citation

A Phase III, Multi-country, Randomized, Placebo-controlled, Double-blinded Trial to Assess the Efficacy and Safety of Tecovirimat Antiviral Treatment for Patients With Monkeypox Virus Disease

TypeinterventionalSponsorANRS, Emerging Infectious DiseasesRan2023 to 2026Enrolled480ConditionsMonkeypox, MpoxArmsTecovirimat, Placebo
3 · Its place in the literature

Who cites it

254 citing papers in PubMed, 12 syntheses or guidelines pooled it, 487 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Therapeutics for treating mpox in humans.The Cochrane database of systematic reviews · 2023
    Pooled it
  9. Pooled it
  10. Pooled it
  11. How can imported monkeypox break the borders? A rapid systematic review.Comparative immunology, microbiology and infectious diseases · 2023
    Pooled it
  12. Pooled it
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. A rapidly developing outbreak of clade Ib mpox among gay, bisexual and other men who have sex with men associated with severe proctitis, Northern Ireland, June 2026.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2026
    Article
  19. Review
  20. Review

194 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

24 authors at 3 institutions in 1 country.

Nicolò GiromettiDepartment of HIV/GUM, Chelsea and Westminster Hospital NHS Foundation Trust, London, UK. Electronic address: n.girometti@nhs.net.
Ruth ByrneDepartment of HIV/GUM, Chelsea and Westminster Hospital NHS Foundation Trust, London, UK.
Margherita BracchiDepartment of HIV/GUM, Chelsea and Westminster Hospital NHS Foundation Trust, London, UK.
Joseph HeskinDepartment of HIV/GUM, Chelsea and Westminster Hospital NHS Foundation Trust, London, UK.
Alan McOwanDepartment of HIV/GUM, Chelsea and Westminster Hospital NHS Foundation Trust, London, UK.
Victoria TittleDepartment of HIV/GUM, Chelsea and Westminster Hospital NHS Foundation Trust, London, UK.
Keerti GedelaDepartment of HIV/GUM, Chelsea and Westminster Hospital NHS Foundation Trust, London, UK.
Christopher ScottDepartment of HIV/GUM, Chelsea and Westminster Hospital NHS Foundation Trust, London, UK.
Sheel PatelDepartment of HIV/GUM, Chelsea and Westminster Hospital NHS Foundation Trust, London, UK.
Jesal GohilDepartment of HIV/GUM, Chelsea and Westminster Hospital NHS Foundation Trust, London, UK.
Diarmuid NugentDepartment of HIV/GUM, Chelsea and Westminster Hospital NHS Foundation Trust, London, UK.
Tara SuchakDepartment of HIV/GUM, Chelsea and Westminster Hospital NHS Foundation Trust, London, UK.
Molly DickinsonDepartment of HIV/GUM, Chelsea and Westminster Hospital NHS Foundation Trust, London, UK.
Margaret FeeneyDepartment of HIV/GUM, Chelsea and Westminster Hospital NHS Foundation Trust, London, UK.
Borja Mora-PerisDepartment of HIV/GUM, Chelsea and Westminster Hospital NHS Foundation Trust, London, UK; Imperial College Healthcare NHS Trust, London, UK.
Katrina StegmannDepartment of HIV/GUM, Chelsea and Westminster Hospital NHS Foundation Trust, London, UK; Falcon Road Clinic (Wandsworth), Central London Community Healthcare NHS Trust, London, UK.
Komal PlahaDepartment of HIV/GUM, Chelsea and Westminster Hospital NHS Foundation Trust, London, UK; Falcon Road Clinic (Wandsworth), Central London Community Healthcare NHS Trust, London, UK.
Gary DaviesDepartment of HIV/GUM, Chelsea and Westminster Hospital NHS Foundation Trust, London, UK.
Luke S P MooreDepartment of HIV/GUM, Chelsea and Westminster Hospital NHS Foundation Trust, London, UK; Imperial College Healthcare NHS Trust, London, UK; Department of Infectious Diseases, Imperial College London, London, UK.
Nabeela MughalDepartment of HIV/GUM, Chelsea and Westminster Hospital NHS Foundation Trust, London, UK; Imperial College Healthcare NHS Trust, London, UK; Department of Infectious Diseases, Imperial College London, London, UK.
David AsboeDepartment of HIV/GUM, Chelsea and Westminster Hospital NHS Foundation Trust, London, UK.
Marta BoffitoDepartment of HIV/GUM, Chelsea and Westminster Hospital NHS Foundation Trust, London, UK; Department of Infectious Diseases, Imperial College London, London, UK.
Rachael JonesDepartment of HIV/GUM, Chelsea and Westminster Hospital NHS Foundation Trust, London, UK.
Gary WhitlockDepartment of HIV/GUM, Chelsea and Westminster Hospital NHS Foundation Trust, London, UK.
Chelsea and Westminster Hospital NHS Foundation Trust · GBCentral London Community Healthcare NHS Trust · GBImperial College London · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHistorically, human monkeypox virus cases in the UK have been limited to imported infections from west Africa. Currently, the UK and several other countries are reporting a rapid increase in monkeypox cases among individuals attending sexual health clinics, with no apparent epidemiological links to endemic areas. We describe demographic and clinical characteristics of patients diagnosed with human monkeypox virus attending a sexual health centre.

methodsIn this observational analysis, we considered patients with confirmed monkeypox virus infection via PCR detection attending open-access sexual health clinics in London, UK, between May 14 and May 25, 2022. We report hospital admissions and concurrent sexually transmitted infection (STI) proportions, and describe our local response within the first 2 weeks of the outbreak.

findingsMonkeypox virus infection was confirmed in 54 individuals, all identifying as men who have sex with men (MSM), with a median age of 41 years (IQR 34-45). 38 (70%) of 54 individuals were White, 26 (48%) were born in the UK, and 13 (24%) were living with HIV. 36 (67%) of 54 individuals reported fatigue or lethargy, 31 (57%) reported fever, and ten (18%) had no prodromal symptoms. All patients presented with skin lesions, of which 51 (94%) were anogenital. 37 (89%) of 54 individuals had skin lesions affecting more than one anatomical site and four (7%) had oropharyngeal lesions. 30 (55%) of 54 individuals had lymphadenopathy. One in four patients had a concurrent STI. Five (9%) of 54 individuals required admission to hospital, mainly due to pain or localised bacterial cellulitis requiring antibiotic intervention or analgesia. We recorded no fatal outcomes.

interpretationAutochthonous community monkeypox virus transmission is currently observed among MSM in the UK. We found a high proportion of concomitant STIs and frequent anogenital symptoms, suggesting transmissibility through local inoculation during close skin-to-skin or mucosal contact, during sexual activity. Additional resources are required to support sexual health and other specialist services in managing this condition. A review of the case definition and better understanding of viral transmission routes are needed to shape infection control policies, education and prevention strategies, and contact tracing.

fundingNone.

Indexed as

Mpox, MonkeypoxSexual and Gender MinoritiesSexual HealthSexually Transmitted DiseasesAdultDemographyHomosexuality, MaleHumansLondonMaleMiddle AgedMonkeypox virusObservational Studies as TopicSexual Behavior

Identifiers

PMID35785793
PMCPMC9534773
OpenAlexW4283771170

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.